FindTrial
Sign In

Multicenter Prospective Cohort Study of Bicyclol Tablets in the Treatment of Antitubercular Agents Induced Liver Injury

Multicenter Prospective Cohort Study of Bicyclol Tablets in the Treatment of Antitubercular Agents Induced Liver Injury

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057209
Enrollment
Unknown
Registered
2022-03-03
Start date
2022-03-04
Completion date
Unknown
Last updated
2023-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced liver injury caused by antitubercular agents

Interventions

Case series:bicyclol tablets

Sponsors

Beijing Chest Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Consistent with the clinical diagnosis of drug-induced liver injury, RUCAM causality assessment scale score >=6; 2. Serum ALT>=1.5 ULN; 3. Liver injury <=6 months; 4. Patients who need to be treated with dicyclol tablets as judged by the treating doctor; 5. Patients who signed informed consent forms.

Exclusion criteria

Exclusion criteria: 1. Liver decompensation; 2. Patients with prophylactic use of bicyclic alcohol; 3. Pregnant or lactating patients or patients of childbearing age who are planning to become pregnant; 4. Any circumstances deemed inappropriate for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
Liver biochemistry;—

Countries

China

Contacts

Public ContactDuan Hongfei

Beijing Chest Hospital, Capital Medical University

duanhongfei@hotmail.com+86 10 89509343

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026